{"id":"NCT00430950","sponsor":"Daiichi Sankyo","briefTitle":"Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension","officialTitle":"Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide Combination 20/25 mg Versus 40/25 mg in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 40 mg Monotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-02","primaryCompletion":"2008-05","completion":"2008-10","firstPosted":"2007-02-02","resultsPosted":"2009-04-20","lastUpdate":"2019-01-10"},"enrollment":1011,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Essential Hypertension"],"interventions":[{"type":"DRUG","name":"olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets","otherNames":[]},{"type":"DRUG","name":"olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"The study will evaluate the blood pressure lowering effects of two different dosages of the combination of olmesartan and hydrochlorothiazide in patients with moderate or severe high blood pressure.","primaryOutcome":{"measure":"Change in Mean Trough Sitting Diastolic Blood Pressure","timeFrame":"8 weeks","effectByArm":[{"arm":"OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo","deltaMin":-11.16,"sd":8.851},{"arm":"OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo","deltaMin":-10.45,"sd":7.928}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2648"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":5},"locations":{"siteCount":41,"countries":["Belgium","Germany","Netherlands","Slovakia"]},"refs":{"pmids":["22114906"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":null,"commonTop":[]}}